EA027928B1 - СИНТЕЗ ПИРРОЛО[2,3-b]ПИРИДИНОВ - Google Patents
СИНТЕЗ ПИРРОЛО[2,3-b]ПИРИДИНОВ Download PDFInfo
- Publication number
- EA027928B1 EA027928B1 EA201492165A EA201492165A EA027928B1 EA 027928 B1 EA027928 B1 EA 027928B1 EA 201492165 A EA201492165 A EA 201492165A EA 201492165 A EA201492165 A EA 201492165A EA 027928 B1 EA027928 B1 EA 027928B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyrrolo
- compound
- added
- mol
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
В изобретении представлено соединение формулы
Description
Настоящая заявка в соответствии со сводом законов США, раздел 35, § 119(е), испрашивает приоритет предварительной заявки на патент США № 61/653994, поданной 31 мая 2012 года, полное содержание которой включено в настоящий документ посредством ссылки.
Область техники
Настоящее изобретение относится к конкретному гетероциклическому соединению.
Уровень техники
Н-[3-[5-(4-хлорфенил)-1Н-пирроло[2,3-Ь]пиридин-3-карбонил]-2,4-дифторфенил]пропан-1-сульфонамид или пропан-1-сульфоновой кислоты {3-[5-(4-хлорфенил)-1Н-пирроло[2,3-Ь]пиридин-3-карбонил]2,4-дифторфенил}амид (вемурафениб; 7е1ЬогаГ™) эффективен для лечения различных В-гаГ опосредованных заболеваний и состояний, включая, но не ограничиваясь ими, метастатическую меланому, рак щитовидной железы и рак толстой и прямой кишки (ЛаШте, 2010, 467, 596-599; Ие\у Епц1апс1 1оитпа1 оГ МеЙ1С1пе, 2010, 363, 80). Указанное соединение и его синтез описаны в публикациях патентов РСТ №№ АО 2007/002433 и АО 2007/002325. Сохраняется интерес к разработке других универсальных и легких способов эффективного получения этой и других биологически активных молекул, в частности, в промышленном масштабе.
В одном аспекте настоящего изобретения представлено соединение формулы
Подробное описание изобретения
Настоящее изобретение относится к новому соединению формулы
В одном аспекте настоящего изобретения представлено соединение формулы
Следующие примеры представлены для иллюстрации, но не для ограничения заявленного изобретения.
Некоторые молекулы, заявленные в настоящем патенте, могут существовать в различных энантиомерных и диастереомерных формах, и все такие варианты этих соединений являются заявленными.
Специалистам в данной области техники понятно также, что при выполнении стандартных приемов выделения в органической химии зачастую используют кислоты и основания. Иногда, если они обладают необходимой естественной кислотностью или основностью, при выполнении экспериментальных способов, описанных в настоящем патенте, образуются соли исходных соединений.
Пример 1. Получение (5-бром-1 Н-пирроло [2,3-Ь] пиридин-3 -ил)-(2,6-дифтор-3 -нитро-фенил)метанона (3).
- 1 027928
В 50 л колбу добавили 1,2-дихлорэтан (ДХЭ, 20 л), затем 5-бромазаиндол (1) (2 кг, 10,152 моль) с получением оранжевой взвеси. В колбу медленно добавили хлорид алюминия (5,421 кг, 40,608 моль). При добавлении первых 1,5 кг наблюдали выделение тепла с образованием темного раствора. Добавили остальное количество А1С13 с получением реакционной смеси. К реакционной смеси добавили 2,6дифтор-3-нитробензоилхлорид 2 (2,25 кг, 10,125 моль) через капельную воронку за период 1,5 ч. Во время добавления температуру реакционной смеси поддерживали при 45°С или ниже. После добавления реакционную смесь перемешивали при 50°С в течение ночи, охладили до комнатной температуры (~22°С) и перенесли в две отдельные 20 л колбы. В 50 л колбу добавили воду (25 л) и ацетонитрил (12 л) и охладили до 0°С. Реакционную смесь погасили добавлением раствора воды/ацетонитрила, поддерживая температуру при 40°С или ниже. Полученную смесь отфильтровали, а фильтрат промыли смесью ацетонитрила:воды (1:1, 2x4 л), водой (4 л) и ацетонитрилом (4 л), затем высушили в вакууме. Получили соединение 3 (2,948 кг, выход 73,4%). М8 (Ε8Ι): М+Н+=382,9 и 383,9. 1Н ЯМР (ДМСО-ά6, δ м.д.): 7,55 (1Н, т), 8,47 (2Н, т), 8,53 (1Н, ά, 1=2,2 Гц), 8,65 (1Н, ά, 1=2,2 Гц), 13,25 (1Н, з).
Пример 2. Получение (3-амино-2,6-дифторфенил)-(5-бром-1Н-пирроло[2,3-Ь]пиридин-3ил)метанона (4)
В 50 л колбу добавили 2-метил-тетрагидрофуран (2-метил-ТГФ) (36 л), соединение 3 (2,85 кг, 7,455 моль) и хлорид олова (ΙΙ) (5,03 кг, 22,365 моль). Смесь нагревали до 60°С. После завершения реакции смесь погасили водным раствором карбоната калия (20%). Полученную смесь отфильтровали через целит, а твердый остаток промыли 2-метил-ТГФ и тетрагидрофураном (ТГФ). Фильтрат промыли водным раствором \аС’1 (15 л, 10%), и отделили органический слой. Органический слой дополнительно промыли водным раствором \аС’1 (15 л, 20%) и концентрировали на ротационном испарителе с получением соединения 4 (2,536 кг, выход 96,65%). М8 (Ε8Ι): М+Н+=353 и 354. 1Н ЯМР (ДМСО- ά6, δ м.д.): 5,22 (2Н, з), 6,93 (2Н, т), 8,12 (1Н, з), 8,47 (1Н, ά 1=2,3 Гц), 8,54 (1Н, ά 1=1,6 Гц), 13,2 (1Н, з).
Пример 3. Получение (3-амино-2,6-дифторфенил)-[5-бром-1-(2,6-дихлорбензоил)пирроло[2,3Ь]пиридин-3-ил]метанона (5)
Соединение 4 (2,5 кг, 7,114 моль), полученное в примере 2, добавили в 50 л колбу и охладили до 9,3°С. К соединению 4 в 50 л колбе добавили триэтиламин (0,864 мг, 8,537 моль), затем 4диметиламинопиридин (ΏΜΑΡ) (0,087 кг, 0,7114 моль) и 2,6-дихлорбензоилхлорид (1,34 кг, 6,40 моль) в 2-метил-ТГФ (25 л) за период времени 2 ч. Реакцию погасили метанолом (0,30 л) при комнатной температуре и добавили водный раствор \аС’1 (12,5 л, 15%) и целит (0,5 кг). Смесь перемешали и отфильтровали через целит. Фильтрат концентрировали и добавили 5 объемов гептана. Полученный раствор перемешивали в течение около 1 ч, высушили при помощи сульфата натрия (1 кг) и отфильтровали. Соединение 5 выделили удалением растворителей под вакуумом (3,47 кг, выход 92,93%). М8 (Ε8Ι): М+Н+=524, 525,8, 527,8. 1Н ЯМР (ДМСО-ά6, δ м.д.): 5,36 (2Н, з), 7,01 (2Н, т), 7,68 (3Н, з), 8,34 (1Н, Ьгз), 8,61 (1Н, Ьгз), 8,72 (1Н, ά 1=2,3 Гц).
Специалистам в данной области техники понятно, что настоящее изобретение хорошо подходит для достижения упомянутых, а также присущих ему целей и преимуществ. Способы, варианты и композиции, описанные в настоящем документе, представлены в качестве иллюстрации предпочтительных вариантов реализации, и они являются лишь примерными и не предназначены для ограничения рамок на- 2 027928 стоящего изобретения. Специалистам в данной области техники понятны изменения в них и в других применениях, которые охвачены общей идеей изобретения и определены в рамках формулы изобретения.
Хотя настоящее изобретение было описано со ссылкой на конкретные варианты реализации, понятно, что другие варианты реализации и альтернативы настоящего изобретения могут быть разработаны специалистами в данной области техники без отклонения от реальной идеи и рамок настоящего изобретения.
Claims (1)
- ФОРМУЛА ИЗОБРЕТЕНИЯСоединение формулы
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653994P | 2012-05-31 | 2012-05-31 | |
US13/793,917 US9150570B2 (en) | 2012-05-31 | 2013-03-11 | Synthesis of heterocyclic compounds |
PCT/US2013/043400 WO2013181415A1 (en) | 2012-05-31 | 2013-05-30 | Synthesis of pyrrolo [2, 3 - b] pyridines |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201492165A1 EA201492165A1 (ru) | 2015-05-29 |
EA027928B1 true EA027928B1 (ru) | 2017-09-29 |
Family
ID=48577959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201492165A EA027928B1 (ru) | 2012-05-31 | 2013-05-30 | СИНТЕЗ ПИРРОЛО[2,3-b]ПИРИДИНОВ |
Country Status (25)
Country | Link |
---|---|
US (2) | US9150570B2 (ru) |
EP (1) | EP2861591B1 (ru) |
JP (1) | JP6258301B2 (ru) |
KR (1) | KR102078429B1 (ru) |
CN (2) | CN104507937A (ru) |
AR (1) | AR091159A1 (ru) |
AU (1) | AU2013267325B2 (ru) |
BR (1) | BR112014029454B1 (ru) |
CA (1) | CA2874555C (ru) |
CL (1) | CL2014003228A1 (ru) |
CR (1) | CR20140576A (ru) |
EA (1) | EA027928B1 (ru) |
EC (1) | ECSP14033037A (ru) |
ES (1) | ES2687300T3 (ru) |
HK (1) | HK1206010A1 (ru) |
IL (1) | IL235819B (ru) |
MX (1) | MX2014014465A (ru) |
MY (1) | MY168935A (ru) |
NZ (1) | NZ630453A (ru) |
PE (1) | PE20142335A1 (ru) |
PH (1) | PH12014502613A1 (ru) |
SG (1) | SG11201407851RA (ru) |
TW (1) | TWI603970B (ru) |
UY (1) | UY34825A (ru) |
WO (1) | WO2013181415A1 (ru) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN110269838A (zh) | 2009-04-03 | 2019-09-24 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
CA2779574C (en) | 2009-11-05 | 2018-12-18 | Rhizen Pharmaceuticals S.A. | Novel kinase modulators |
CA2780190C (en) | 2009-11-06 | 2020-05-05 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN105906631A (zh) | 2009-11-18 | 2016-08-31 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
JP5815558B2 (ja) | 2009-12-23 | 2015-11-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節のための化合物及び方法ならびにそれらの適応症 |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
LT2672967T (lt) | 2011-02-07 | 2018-12-10 | Plexxikon Inc. | Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos |
JP6113151B2 (ja) | 2011-05-17 | 2017-04-12 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節およびその適応症 |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
TWI601725B (zh) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
EP2892534B8 (en) | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
SG10201707095QA (en) | 2012-12-21 | 2017-09-28 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
CA2903293C (en) | 2013-03-15 | 2020-10-13 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
SG11201509338QA (en) | 2013-05-30 | 2015-12-30 | Plexxikon Inc | Compounds for kinase modulation, and indications therefor |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
EP3223817A4 (en) | 2014-11-29 | 2018-05-30 | Shilpa Medicare Limited | Substantially pure vemurafenib and its salts |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI660956B (zh) | 2015-05-06 | 2019-06-01 | 美商普雷辛肯公司 | 調節蛋白質激酶之化合物的合成 |
TWI727949B (zh) | 2015-05-06 | 2021-05-21 | 美商普雷辛肯公司 | 調節蛋白質激酶之化合物的固態形式 |
WO2016191303A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20181093A1 (es) | 2015-09-21 | 2018-07-09 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos |
AU2016367147B2 (en) | 2015-12-07 | 2021-04-08 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017161045A1 (en) | 2016-03-16 | 2017-09-21 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
EP3558991A2 (en) | 2016-12-23 | 2019-10-30 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
ES2896502T3 (es) | 2017-03-20 | 2022-02-24 | Plexxikon Inc | Formas cristalinas de ácido 4-(1-(1,1-di(piridin-2-il) etil)-6-(3,5-dimetilisoxazol-4-il)-1H-pirrolo[3,2-b]piridin-3- il)benzoico que inhiben el bromodominio |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
KR102051625B1 (ko) * | 2017-06-30 | 2019-12-02 | 주식회사 엘지화학 | 신규한 헤테로 고리 화합물 및 이를 이용한 유기 발광 소자 |
CN110944670B (zh) | 2017-07-25 | 2023-03-10 | 普莱希科公司 | 调制激酶的化合物的制剂 |
US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
JP7175309B2 (ja) | 2017-10-27 | 2022-11-18 | プレキシコン インコーポレーテッド | キナーゼを調節する化合物の製剤 |
CN112119072A (zh) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | 用于ido和tdo调节的化合物和方法,以及其适应症 |
CA3136224A1 (en) | 2019-04-09 | 2020-10-15 | Plexxikon Inc. | Condensed azines for ep300 or cbp modulation and indications therefor |
AU2021261383A1 (en) | 2020-04-23 | 2022-11-17 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
CN116322690A (zh) | 2020-08-21 | 2023-06-23 | 奥普纳生物有限公司 | 组合的药物抗癌疗法 |
US11578971B2 (en) | 2021-02-12 | 2023-02-14 | Holloway Ndt & Engineering Inc. | Ultrasonic testing using a phased array |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002325A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
WO2010129567A1 (en) * | 2009-05-06 | 2010-11-11 | Plexxikon, Inc. | Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase |
WO2011079133A2 (en) * | 2009-12-23 | 2011-06-30 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2012032236A1 (fr) * | 2010-09-09 | 2012-03-15 | Giroptic | Dispositif optique pour la capture d'images selon un champ de 360 ° |
Family Cites Families (298)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB145299A (en) | 1919-08-14 | 1920-07-02 | Carl Theodor Thorssell | Improvements in or relating to apparatus for the production of nitrogen products |
US2234705A (en) | 1940-04-12 | 1941-03-11 | Eastman Kodak Co | Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids |
US2413258A (en) | 1942-07-07 | 1946-12-24 | United Gas Improvement Co | Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters |
CH513136A (de) | 1966-10-21 | 1971-09-30 | Minnesota Mining & Mfg | Verfahren zur Herstellung N-substituierter, einen Perfluorkohlenstoffrest aufweisender Sulfonamide |
IL46853A0 (en) | 1974-03-20 | 1975-05-22 | Bayer Ag | Novel alkoxycarbonylphenylureas,their preparation and their use as herbicides |
GB1573212A (en) | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
CA1148562A (en) * | 1979-02-22 | 1983-06-21 | Alfred J. Bird | Catalyst for the hydrogenation of halogen substituted aromatic nitro compounds |
US4301159A (en) | 1980-06-20 | 1981-11-17 | Shionogi & Co., Ltd. | N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives |
AU547405B2 (en) | 1981-07-08 | 1985-10-17 | Sanofi | Amidobenzamides |
US4664504A (en) | 1983-01-20 | 1987-05-12 | Tokyo Shibaura Denki Kabushiki Kaisha | Image forming apparatus |
US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
AU567140B2 (en) | 1984-01-06 | 1987-11-12 | Shionogi & Co., Ltd. | Sulphonamido-benzamide derivatives |
EP0154734B1 (en) | 1984-03-15 | 1990-08-29 | Immunex Corporation | Immediate ligand detection assay, a test kit and its formation |
IT1196133B (it) | 1984-06-06 | 1988-11-10 | Ausonia Farma Srl | Derivati furanici con attivita' antiulcera |
US4714693A (en) | 1986-04-03 | 1987-12-22 | Uop Inc. | Method of making a catalyst composition comprising uniform size metal components on carrier |
DE3642315A1 (de) | 1986-12-11 | 1988-06-23 | Boehringer Mannheim Gmbh | Neue pyrrolobenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
US5688655A (en) | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5658775A (en) | 1988-05-17 | 1997-08-19 | Sloan-Kettering Institute For Cancer Research | Double copy retroviral vector |
JP2528706B2 (ja) | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
CA1339354C (en) | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
FR2649979B1 (fr) * | 1989-07-20 | 1992-01-17 | Rhone Poulenc Chimie | Procede d'hydrogenation de derives halogeno nitroaromatiques en presence d'un derive soufre |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
DE4022414A1 (de) | 1990-07-13 | 1992-01-16 | Bayer Ag | Substituierte pyrrolo-pyridine |
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
ATE159426T1 (de) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
EP0659209A1 (en) | 1991-07-26 | 1995-06-28 | The University Of Rochester | Cancer therapy utilizing malignant cells |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
GB9127531D0 (en) | 1991-12-31 | 1992-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compound |
FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
JPH05236997A (ja) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | ポリヌクレオチド捕捉用チップ |
JPH06135946A (ja) | 1992-10-30 | 1994-05-17 | Otsuka Pharmaceut Co Ltd | ピラジン誘導体 |
AU686115B2 (en) | 1992-11-02 | 1998-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
CA2156410A1 (en) | 1993-03-01 | 1994-09-15 | Raymond Baker | Pyrrolo-pyridine derivatives |
US5576319A (en) | 1993-03-01 | 1996-11-19 | Merck, Sharp & Dohme Ltd. | Pyrrolo-pyridine derivatives |
ES2134929T3 (es) | 1993-03-01 | 1999-10-16 | Merck Sharp & Dohme | Derivados de pirrolo-piridina como ligandos para receptores de dopamina. |
CZ224195A3 (en) | 1993-03-01 | 1996-03-13 | Merck Sharp & Dohme | The use of pyrrolopyridine derivatives for preparing pharmaceutical preparations |
WO1994028028A1 (en) | 1993-05-27 | 1994-12-08 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
US5840485A (en) | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
IT1265057B1 (it) | 1993-08-05 | 1996-10-28 | Dompe Spa | Tropil 7-azaindolil-3-carbossiamidi |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
GB9319297D0 (en) | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5360882A (en) | 1994-02-04 | 1994-11-01 | Isp Investments Inc. | Eutectic compositions of divinyl imidazolidone and vinyl caprolactam |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
GB9408577D0 (en) | 1994-04-29 | 1994-06-22 | Fujisawa Pharmaceutical Co | New compound |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
GB9412719D0 (en) | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
US5763198A (en) | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
US5830901A (en) | 1994-08-10 | 1998-11-03 | Merch Sharp & Dohme Ltd | Tetrahydropyridinylmethyl derivatives of pyrrolo 2,3-B!pyridine |
GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB9416162D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5837815A (en) | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
GB9503400D0 (en) | 1995-02-21 | 1995-04-12 | Merck Sharp & Dohme | Therpeutic agents |
GB2298199A (en) | 1995-02-21 | 1996-08-28 | Merck Sharp & Dohme | Synthesis of azaindoles |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US6117681A (en) | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
GB2299581A (en) | 1995-04-07 | 1996-10-09 | Merck Sharp & Dohme | 3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes |
GB9507291D0 (en) | 1995-04-07 | 1995-05-31 | Merck Sharp & Dohme | Therapeutic agents |
GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
US5866411A (en) | 1995-09-08 | 1999-02-02 | Pedersen; Finn Skou | Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector |
US5747276A (en) | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
US5721118A (en) | 1995-10-31 | 1998-02-24 | The Regents Of The University Of California, San Diego | Mammalian artificial chromosomes and methods of using same |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
US5908401A (en) | 1996-05-08 | 1999-06-01 | The Aps Organization, Llp | Method for iontophoretic delivery of antiviral agents |
US5725838A (en) | 1996-05-31 | 1998-03-10 | Resolution Pharmaceuticals, Inc. | Radiolabeled D4 receptor ligands |
US6057100A (en) | 1996-06-07 | 2000-05-02 | Eos Biotechnology, Inc. | Oligonucleotide arrays |
WO1997049703A2 (en) | 1996-06-25 | 1997-12-31 | Takeda Chemical Industries, Ltd. | Oxazolone derivatives and their use as anti-helicobacter pylori agents |
EP0956865B2 (en) | 1996-08-12 | 2010-08-18 | Mitsubishi Tanabe Pharma Corporation | MEDICINES COMPRISING Rho KINASE INHIBITOR |
JPH10130269A (ja) | 1996-09-04 | 1998-05-19 | Nippon Chemiphar Co Ltd | カルボリン誘導体 |
JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
IL129928A0 (en) | 1996-11-19 | 2000-02-29 | Amgen Inc | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
JP2001514506A (ja) | 1997-03-07 | 2001-09-11 | トロピックス・インコーポレーテッド | プロテアーゼ阻害剤分析 |
US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
WO1998047899A1 (en) | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
SG72827A1 (en) | 1997-06-23 | 2000-05-23 | Hoffmann La Roche | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives |
AU8096798A (en) | 1997-06-27 | 1999-01-19 | Resolution Pharmaceuticals Inc. | Dopamine d4 receptor ligands |
US6235769B1 (en) | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
US6826296B2 (en) | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
US6161776A (en) | 1997-08-12 | 2000-12-19 | Nibco Inc. | Multi-layered, porous mat turf irrigation apparatus and method |
JP2001514906A (ja) | 1997-08-15 | 2001-09-18 | ハイセック,インコーポレーテッド | 核酸種を検出または定量するための方法および組成物 |
CN1677076A (zh) | 1997-09-11 | 2005-10-05 | 生物风险公司 | 制备高密度阵列的方法 |
US6178384B1 (en) | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
US6465178B2 (en) | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
DE69831013T2 (de) | 1997-12-22 | 2006-04-20 | Bayer Pharmaceuticals Corp., West Haven | Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen |
AU1529799A (en) | 1997-12-23 | 1999-07-12 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
JP2002510685A (ja) | 1998-04-02 | 2002-04-09 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
WO1999051231A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JP2002510631A (ja) | 1998-04-02 | 2002-04-09 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
AU3118399A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
AU3210799A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
EP1066285A1 (en) | 1998-04-02 | 2001-01-10 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6288234B1 (en) | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
EP1459742B9 (en) | 1998-08-17 | 2012-05-02 | Senju Pharmaceutical Co., Ltd. | Agent for prophylaxis and treatment of asthenopia and pseudomyopia |
EP1107758A2 (en) | 1998-08-28 | 2001-06-20 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
DE69912618T2 (de) | 1998-08-28 | 2004-10-28 | Astrazeneca Ab | NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE |
US6594527B2 (en) | 1998-09-18 | 2003-07-15 | Nexmed Holdings, Inc. | Electrical stimulation apparatus and method |
BR9913888A (pt) | 1998-09-18 | 2002-01-08 | Basf Ag | Composto, e, métodos de inibir a atividade da proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente |
US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
IT1303759B1 (it) | 1998-11-17 | 2001-02-23 | Dompe Spa | Procedimento migliorato per la preparazione di acido 7-azaindolil-3-carbossilico. |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20010001449A1 (en) | 1998-12-30 | 2001-05-24 | Thomas R. Kiliany | Low-pressure hydrocracking process |
CN1198803C (zh) | 1999-03-05 | 2005-04-27 | 第一三得利制药株式会社 | 具有激活烟碱性乙酰胆碱α4β2受体作用的杂环化合物 |
US6792306B2 (en) | 2000-03-10 | 2004-09-14 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor |
US7008945B1 (en) | 1999-03-17 | 2006-03-07 | Astrazeneca Ab | Amide derivatives |
AR028475A1 (es) | 1999-04-22 | 2003-05-14 | Wyeth Corp | Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion. |
US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
US6221653B1 (en) | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
FR2793793B1 (fr) | 1999-05-19 | 2004-02-27 | Adir | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6492406B1 (en) | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
TWI234557B (en) | 1999-05-26 | 2005-06-21 | Telik Inc | Novel naphthalene ureas as glucose uptake enhancers |
EP1181282A2 (en) | 1999-06-03 | 2002-02-27 | Basf Aktiengesellschaft | Benzothiazinone and benzoxazinone compounds |
TR200200928T2 (tr) | 1999-07-30 | 2002-09-23 | Abbott Gmbh & Co.Kg | 2-pirazolin-5-on terkipleri |
US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
WO2001024236A1 (en) | 1999-09-27 | 2001-04-05 | Infineon Technologies North America Corp. | Semiconductor structures having a capacitor and manufacturing methods |
GB9924962D0 (en) | 1999-10-21 | 1999-12-22 | Mrc Collaborative Centre | Allosteric sites on muscarinic receptors |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
ATE299881T1 (de) | 1999-12-21 | 2005-08-15 | Sugen Inc | 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren |
DK1255536T3 (da) | 1999-12-22 | 2006-10-30 | Sugen Inc | Indolinonderivater til modulation af c-kit-tyrosinproteinkinase |
FR2805259B1 (fr) | 2000-02-17 | 2002-03-29 | Inst Nat Sante Rech Med | Nouveaux derives d'aminoacides n-mercaptoacyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20020061892A1 (en) | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
JP2001278886A (ja) | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | ベンゾオキサジン誘導体及びこれを含有する医薬 |
GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
PL359563A1 (en) | 2000-06-26 | 2004-08-23 | Pfizer Products Inc. | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
AU2001266575A1 (en) | 2000-06-26 | 2002-01-08 | Lilly Icos Llc | Chemical compounds |
MXPA03001785A (es) | 2000-08-31 | 2003-06-04 | Pfizer Prod Inc | Derivados de pirazol y su uso como inhibidores de proteina cinasa. |
US6618625B2 (en) | 2000-11-29 | 2003-09-09 | Leon M. Silverstone | Method and apparatus for treatment of viral diseases |
CN1503662A (zh) | 2001-02-27 | 2004-06-09 | 药物制剂 | |
US7109208B2 (en) | 2001-04-11 | 2006-09-19 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents |
AU2002258971A1 (en) | 2001-04-24 | 2002-11-05 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan |
GB0114417D0 (en) | 2001-06-13 | 2001-08-08 | Boc Group Plc | Lubricating systems for regenerative vacuum pumps |
EP1267111A1 (en) | 2001-06-15 | 2002-12-18 | Dsm N.V. | Pressurized fluid conduit |
US20040171630A1 (en) | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
US7291639B2 (en) | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
UA75425C2 (en) | 2001-07-09 | 2006-04-17 | Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds | |
GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
US6858860B2 (en) | 2001-07-24 | 2005-02-22 | Seiko Epson Corporation | Apparatus and method for measuring natural period of liquid |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
JP2003073357A (ja) | 2001-09-03 | 2003-03-12 | Mitsubishi Pharma Corp | アミド化合物を含有するRhoキナーゼ阻害剤 |
WO2003020698A2 (en) | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
EP1452525A4 (en) | 2001-10-30 | 2005-01-26 | Nippon Shinyaku Co Ltd | AMIDE DERIVATIVES AND CORRESPONDING MEDICAMENTS |
US20030119839A1 (en) | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
DK1470124T3 (da) | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
ATE549329T1 (de) | 2002-02-01 | 2012-03-15 | Astrazeneca Ab | Chinazoline verbindungen |
US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
US6884889B2 (en) | 2002-03-25 | 2005-04-26 | Bristol-Myers Squibb Co. | Processes for the preparation of antiviral 7-azaindole derivatives |
CN100368411C (zh) | 2002-03-28 | 2008-02-13 | 卫材R&D管理有限公司 | 作为c-Jun N-末端激酶抑制剂用于治疗神经变性疾病的7-氮杂吲哚类化合物 |
JP2005534619A (ja) | 2002-03-28 | 2005-11-17 | エーザイ株式会社 | C−junn−末端キナーゼ阻害剤としてのアザインドール |
WO2003087087A2 (en) | 2002-04-09 | 2003-10-23 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
AU2003247959B2 (en) | 2002-07-09 | 2010-07-29 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6878887B2 (en) | 2002-08-07 | 2005-04-12 | Matsushita Electric Industrial Co., Ltd. | Anti-malfunction mechanism for variable output device |
EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
EP1388541A1 (en) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
MXPA05002444A (es) | 2002-09-06 | 2005-09-30 | Insert Therapeutics Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
AU2003272548A1 (en) | 2002-09-16 | 2004-04-30 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
US6766199B2 (en) | 2002-10-10 | 2004-07-20 | Proventure (Far East), Limited | Skin/hair treatment method and system |
US7183241B2 (en) | 2002-10-15 | 2007-02-27 | Exxonmobil Research And Engineering Company | Long life lubricating oil composition with very low phosphorus content |
GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
SE0203654D0 (sv) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
RU2005118407A (ru) | 2002-12-13 | 2006-03-10 | СмитКлайн Бичем Корпорейшн (US) | Производные пиперидина в качестве антагонистов ccr5 |
EP1569647B1 (en) | 2002-12-13 | 2008-08-20 | Smithkline Beecham Corporation | Cyclohexyl compounds as ccr5 antagonists |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
SE0300119D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
US20050085463A1 (en) | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
WO2004069138A2 (en) | 2003-02-03 | 2004-08-19 | Novartis Ag | Pharmaceutical formulation |
CA2515571A1 (en) | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
SE0300456D0 (sv) | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
JP2007524374A (ja) | 2003-02-28 | 2007-08-30 | プレキシコン,インコーポレーテッド | Pyk2結晶構造および使用 |
JP4787150B2 (ja) | 2003-03-06 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Jnk阻害剤 |
US7612086B2 (en) | 2003-05-16 | 2009-11-03 | Eisai R & D Management Co. Ltd. | JNK inhibitors |
PL1648889T3 (pl) | 2003-07-11 | 2009-03-31 | Warner Lambert Co | Sól izetionian selektywnego inhibitora CDK4 |
CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
WO2005028624A2 (en) | 2003-09-15 | 2005-03-31 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
JP2007506741A (ja) | 2003-09-23 | 2007-03-22 | メルク エンド カムパニー インコーポレーテッド | 向代謝性グルタミン酸受容体のピラゾール系調節剤 |
KR100793095B1 (ko) | 2003-10-01 | 2008-01-10 | 주식회사 프로메디텍 | Bace 저해효능을 가진 신규한 술폰 아미드 유도체 |
EP1673343A4 (en) | 2003-10-08 | 2008-09-10 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
DE10357510A1 (de) | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
BRPI0417533B1 (pt) | 2003-12-24 | 2016-03-01 | Danisco | enzima variante glicolipídio aciltransferase, uso e método para sua produção, método para o preparo de um produto alimentício e produto assado de farinha, processo de refinamento enzimático |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
DK1713806T3 (da) | 2004-02-14 | 2013-08-05 | Irm Llc | Forbindelser og sammensætninger som proteinkinaseinhibitorer |
GB0403635D0 (en) | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
GB0405055D0 (en) | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
US20050250820A1 (en) | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제 |
TWI471133B (zh) | 2004-03-30 | 2015-02-01 | Vertex Pharma | 適合作為jak及其它蛋白質激酶抑制劑之氮雜吲哚 |
AU2005236002A1 (en) | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
EP1773305A2 (en) | 2004-05-25 | 2007-04-18 | Yale University Corporation | Method for treating skeletal disorders resulting from fgfr malfunction |
JP4842929B2 (ja) | 2004-05-27 | 2011-12-21 | ファイザー・プロダクツ・インク | 癌治療に有用なピロロピリミジン誘導体 |
WO2005115374A1 (en) | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Crth2 receptor ligands for therapeutic use |
US20060058339A1 (en) | 2004-06-17 | 2006-03-16 | Ibrahim Prabha N | Compounds modulating c-kit activity and uses therefor |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
DK1761520T3 (da) * | 2004-06-23 | 2008-10-27 | Lilly Co Eli | Kinaseinhibitorer |
WO2006004984A1 (en) | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
US7140816B2 (en) | 2004-07-20 | 2006-11-28 | H&S Tool, Inc. | Multi-functional tube milling head |
US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
EP1781654A1 (en) | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
WO2006015124A2 (en) | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US20060024361A1 (en) | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
EP1789393A2 (en) | 2004-07-30 | 2007-05-30 | GPC Biotech AG | Pyridinylamines |
WO2006063167A1 (en) | 2004-12-08 | 2006-06-15 | Smithkline Beecham Corporation | 1h-pyrrolo[2,3-b]pyridines |
AU2006239632B2 (en) | 2005-04-25 | 2012-03-15 | Merck Patent Gmbh | Novel AZA- heterocycles serving as kinase inhibitors |
FR2884821B1 (fr) | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
CA2608733A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
ZA200710379B (en) | 2005-05-20 | 2009-05-27 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
EP1883625A2 (en) | 2005-05-23 | 2008-02-06 | Teva Pharmaceutical Industries Ltd | Amorphous cinacalcet hydrochloride and preparation thereof |
AU2006260299B8 (en) | 2005-06-21 | 2012-11-29 | Mitsui Chemicals, Inc. | Amide derivative and insecticide containing the same |
DE102005034406A1 (de) | 2005-07-22 | 2007-02-01 | Ratiopharm Gmbh | Neue Salze von Rosiglitazon |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
JP2009530415A (ja) | 2006-03-20 | 2009-08-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
US7963673B2 (en) | 2006-05-30 | 2011-06-21 | Finn Bruce L | Versatile illumination system |
SI2848610T1 (en) | 2006-11-15 | 2018-02-28 | Ym Biosciences Australia Pty Ltd | Inhibitors of kinase activity |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
GB0624084D0 (en) | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
US8093246B2 (en) | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
EP2155166A2 (en) | 2007-05-11 | 2010-02-24 | F. Hoffmann-Roche AG | Pharmaceutical compositions for poorly soluble drugs |
CL2008001540A1 (es) | 2007-05-29 | 2009-05-22 | Sgx Pharmaceuticals Inc | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. |
SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
EP2180883B1 (en) | 2007-07-23 | 2017-01-11 | Pharmathen S.A. | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
CA2639416C (en) | 2007-09-11 | 2019-12-31 | F. Hoffmann-La Roche Ag | Diagnostic test for susceptibility to b-raf kinase inhibitors |
EP2265608A2 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
US20110003859A1 (en) | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
EP2265609B1 (en) | 2008-02-29 | 2012-09-05 | Array Biopharma, Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
PE20091623A1 (es) | 2008-02-29 | 2009-11-19 | Array Biopharma Inc | DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA |
WO2009115084A2 (de) | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Neue pyrrolopyrimidin-derivate und deren verwendungen |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
WO2009152087A1 (en) * | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor |
EP2313411A1 (en) * | 2008-06-10 | 2011-04-27 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor |
BRPI0917459B1 (pt) | 2008-08-20 | 2017-09-12 | Zoetis Services Llc | N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide |
ES2548141T3 (es) | 2008-11-20 | 2015-10-14 | Glaxosmithkline Llc | Compuestos químicos |
EP2406260A1 (en) | 2009-03-11 | 2012-01-18 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
BRPI1011515A2 (pt) * | 2009-03-11 | 2016-03-29 | Plexxikon Inc | derivados de pirrolo[2,3-b] piridina para a inibição de raf cinases |
CN110269838A (zh) | 2009-04-03 | 2019-09-24 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
CA2771893A1 (en) * | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
CA2780190C (en) | 2009-11-06 | 2020-05-05 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2011060216A1 (en) * | 2009-11-12 | 2011-05-19 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
CN105906631A (zh) | 2009-11-18 | 2016-08-31 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
US20120208837A1 (en) | 2010-09-13 | 2012-08-16 | Roger Tung | Substituted azaindoles |
LT2672967T (lt) * | 2011-02-07 | 2018-12-10 | Plexxikon Inc. | Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
WO2012138809A1 (en) | 2011-04-05 | 2012-10-11 | Dawei Zhang | Heterocyclic compounds as kinase inhibitors |
JP6113151B2 (ja) | 2011-05-17 | 2017-04-12 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節およびその適応症 |
US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
SG11201509338QA (en) * | 2013-05-30 | 2015-12-30 | Plexxikon Inc | Compounds for kinase modulation, and indications therefor |
WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
-
2013
- 2013-03-11 US US13/793,917 patent/US9150570B2/en active Active
- 2013-05-23 TW TW102118278A patent/TWI603970B/zh active
- 2013-05-24 UY UY0001034825A patent/UY34825A/es not_active Application Discontinuation
- 2013-05-24 AR ARP130101826 patent/AR091159A1/es unknown
- 2013-05-30 EP EP13727790.1A patent/EP2861591B1/en active Active
- 2013-05-30 CN CN201380027442.9A patent/CN104507937A/zh active Pending
- 2013-05-30 CN CN201811515969.7A patent/CN109608450A/zh active Pending
- 2013-05-30 KR KR1020147036080A patent/KR102078429B1/ko active IP Right Grant
- 2013-05-30 EA EA201492165A patent/EA027928B1/ru not_active IP Right Cessation
- 2013-05-30 CA CA2874555A patent/CA2874555C/en active Active
- 2013-05-30 SG SG11201407851RA patent/SG11201407851RA/en unknown
- 2013-05-30 ES ES13727790.1T patent/ES2687300T3/es active Active
- 2013-05-30 JP JP2015515193A patent/JP6258301B2/ja active Active
- 2013-05-30 MY MYPI2014703464A patent/MY168935A/en unknown
- 2013-05-30 AU AU2013267325A patent/AU2013267325B2/en active Active
- 2013-05-30 BR BR112014029454-2A patent/BR112014029454B1/pt active IP Right Grant
- 2013-05-30 NZ NZ630453A patent/NZ630453A/en not_active IP Right Cessation
- 2013-05-30 PE PE2014002209A patent/PE20142335A1/es not_active Application Discontinuation
- 2013-05-30 WO PCT/US2013/043400 patent/WO2013181415A1/en active Application Filing
- 2013-05-30 MX MX2014014465A patent/MX2014014465A/es unknown
-
2014
- 2014-11-20 IL IL23581914A patent/IL235819B/en active IP Right Grant
- 2014-11-24 PH PH12014502613A patent/PH12014502613A1/en unknown
- 2014-11-27 CL CL2014003228A patent/CL2014003228A1/es unknown
- 2014-12-15 CR CR20140576A patent/CR20140576A/es unknown
- 2014-12-23 EC ECIEPI201433037A patent/ECSP14033037A/es unknown
-
2015
- 2015-07-06 HK HK15106422.8A patent/HK1206010A1/xx unknown
- 2015-08-28 US US14/839,668 patent/US9695169B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002325A1 (en) * | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
WO2010129567A1 (en) * | 2009-05-06 | 2010-11-11 | Plexxikon, Inc. | Pyrrolo [2, 3. b] pyridines which inhibit raf protein kinase |
WO2011079133A2 (en) * | 2009-12-23 | 2011-06-30 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2012032236A1 (fr) * | 2010-09-09 | 2012-03-15 | Giroptic | Dispositif optique pour la capture d'images selon un champ de 360 ° |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA027928B1 (ru) | СИНТЕЗ ПИРРОЛО[2,3-b]ПИРИДИНОВ | |
JP7307723B2 (ja) | Pad阻害剤としてのイミダゾ-ピリジン化合物 | |
CA2971872C (en) | Mutant idh1 inhibitors useful for treating cancer | |
CN106132947B (zh) | 化合物的制备方法 | |
CN104903327B (zh) | 用于治疗疼痛的作为autotaxin抑制剂的吡啶并-或吡咯并-稠合嘧啶衍生物 | |
JP6802850B2 (ja) | 大環状化合物および該化合物を含む組成物 | |
JP6294953B2 (ja) | P2x7調節物質 | |
WO2014102377A1 (en) | Azaindole derivatives as multi kinase inhibitors | |
JP2022536773A (ja) | 置換ピラゾロピラジン及びglun2b受容体調節因子としてのそれらの使用 | |
JP2016522195A5 (ru) | ||
JP6837072B2 (ja) | 6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド化合物 | |
WO2019188200A1 (ja) | スルファミン酸リチウムの製造方法及び新規スルファミン酸リチウム | |
AU2018256494B2 (en) | Method for the preparation of (1,2,4)-triazolo(4,3-A)pyridines | |
JP6377676B2 (ja) | 新規なヒドロキサム酸誘導体の製造方法 | |
WO2008041088A2 (en) | N-hydroxy benzamides with antitumor activity | |
CN114573512B (zh) | 一种合成c2-二氟烷基苯并咪唑衍生物的方法 | |
CN104710417A (zh) | 氮杂吲哚类衍生物及其合成方法 | |
US10526363B2 (en) | Substituted phosphoramidate compounds and uses thereof | |
Palacios et al. | Synthesis of novel 2, 5-dihydro-1, 5, 2-diazaphosphinines from primary enamine phosphonates and from alkyl phosphonates | |
CN105503868A (zh) | 一种咪唑并杂环氨基甲酸酯衍生物及其制备方法和应用 | |
JP6592521B2 (ja) | ピラゾール誘導体の製造方法 | |
Zhang et al. | Synthesis of a Sulfonamide Pyruvate Kinase M2 Activator for Cancer Therapy | |
US9464087B2 (en) | Difluoromethylation of unsaturated compounds | |
CN115466259B (zh) | 一种kras g12c抑制剂索托拉西布的制备方法 | |
CN107286074A (zh) | 3‑羟基异吲哚‑1‑酮衍生物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |